Antibody-guided multivalent nanoparticle vaccine against Group A Streptococcus

The incidence of invasive Group A Streptococcus (GAS) reached the highest ever recorded figures in Sweden last year. In the event of an invasive infection, the bacterium spreads like wildfire in the body. Sepsis is difficult to detect at an early stage and the course of the disease is rapid, which is why many people do not seek care in time. A multivalent vaccine that can proactively protect the population against invasive GAS infections would create great societal benefits and save lives.